Max Gelman is a Senior Editor at Endpoints News. He specializes in the intersection of medicine and healthcare, with a keen focus on oncology, immunology, and pharmaceuticals, as well as business and economics within the healthcare system. Max's insights and analyses have been featured in Endpoints News, NewsBreak, and World Wealth Journal.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Max Gelman's articles predominantly cover the healthcare and pharmaceutical industry, with a focus on clinical trials, drug development, and medical research. His coverage heavily relies on cited data and press releases from private sector announcements.
Given Max's reliance on data-driven content, he is likely to be receptive to pitches that offer exclusive access to new findings or insights based on extensive data analysis within the healthcare and pharmaceutical sectors. Additionally, providing expert commentary or analysis of trends in biotech, pharmaceuticals, clinical trials or medical research might also capture his interest.
As Max does not have a specified geographic focus but seems to cover global developments in the industry; therefore sources with an international perspective may resonate well with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Merck provided some of the clearest direction yet regarding its ambitions in oncology to improve on its blockbuster immunotherapy Keytruda.
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
By: Max Gelman, Nicole Defeudis
Welcome back to the Weekly! The Endpoints News team gathered a group of industry experts in Cambridge, MA this week to debate the future of China biotech. During one of ...
By: Nicole DeFeudis, Alex Hoffman, Max Gelman
→ Some big changes are coming at Bicara Therapeutics , and it starts at the top. President and COO Ryan Cohlhepp
By: Max Gelman, Nicole DeFeudis
Welcome back to another edition of Endpoints Weekly! We're in the dog days of summer, but we still have some big stories to recap for …
By: Max Gelman
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
By: Max Gelman
Senior Editor After a turbulent few years researching ALS, Amylyx Pharmaceuticals said it has notched a success in its attempt to rebuild as a GLP-1 biotech.
By: Max Gelman
Merck & Moderna's personalized cancer vaccine intismeran autogene combined with Keytruda succeeded in its first Phase 3 trial, marking the first late-stage success for an mRNA cancer vaccine.
By: Max Gelman
A new biotech aiming to tackle protein misfolding has landed a substantial Series A from some blue-chip investors.
By: Max Gelman, Nicole DeFeudis
Welcome back to Endpoints Weekly! Merck and Moderna dominated the headlines this week with topline results for their personalized cancer vaccine. Check out our team's …
